Research programme: VAP-1 SSAO enzyme inhibitors - Acorda Therapeutics

Drug Profile

Research programme: VAP-1 SSAO enzyme inhibitors - Acorda Therapeutics

Alternative Names: BTT-2027; VAP-1 SMI; VAP-1 SSAO enzyme inhibitor; Vapill

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotie Therapies Corp.
  • Class Small molecules
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 29 Oct 2010 Roche and Biotie Therapies Corp. mutally terminate their agreement
  • 02 Mar 2009 Preclinical development is ongoing
  • 19 Jun 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top